Medicinal-cannabis research in New Zealand

New Zealand’s medicinal-cannabis research landscape sits inside a tightly regulated pharmaceutical framework. The Medicinal Cannabis Scheme, administered by the Medicinal Cannabis Agency (MCA) within Medsafe, has been fully operational since 1 April 2020 under the Misuse of Drugs Act. The scheme legalises access via a prescription from a medical practitioner, and products must meet GMP standards and be approved by the Ministry of Health. The thing newcomers most often get wrong is that “legal medicinal cannabis” does not mean a patient can legally smoke raw plant material or buy unregulated products; the legal product is a manufactured pharmaceutical, and the raw flower, while available, is prescribed and dispensed through a pharmacy, not a dispensary.

This page gives you the verified research picture, the institutions doing the work, and a decision rule for evaluating any claim about medicinal cannabis in New Zealand. If you are a patient, a prescriber, or a sector reader, you will leave with a checklist to separate evidence, regulation, and marketing.

---

What the Medicinal Cannabis Scheme actually is

New Zealand’s Medicinal Cannabis Scheme is a regulated pharmaceutical pathway under the Misuse of Drugs Act, not a general licence to use cannabis. The scheme was created by the Misuse of Drugs (Medicinal Cannabis) Amendment Act 2018 and came fully into force in April 2020. Under the scheme, medicinal cannabis products must meet GMP (Good Manufacturing Practice) standards and be approved by the Ministry of Health through Medsafe. A prescription from a registered medical practitioner is required; there is no over-the-counter access. The raw flower, when prescribed, is a manufactured pharmaceutical product dispensed through a pharmacy, not a dispensary. The key distinction: “legal medicinal cannabis” does not mean a patient can legally smoke raw plant material or buy unregulated products. The legal product is a manufactured pharmaceutical.

This page is part of the Medicinal Cannabis NZ Guide. It answers one question: what does medicinal-cannabis research in New Zealand actually look like, and how can a patient, whānau, or clinician navigate it without confusing marketing with evidence. The page focuses on the regulatory scheme, the institutions that run it, and a practical method for reading research claims.

What counts as medicinal cannabis in New Zealand

Under the Misuse of Drugs Act 1975 and the Misuse of Drugs (Medicinal Cannabis) Regulations 2019, medicinal cannabis is a prescription medicine. The Medicinal Cannabis Scheme, administered by the Medicinal Cannabis Agency (MCA) within Medsafe, sets the legal framework. Products must be manufactured to GMP standards, contain specified amounts of THC and/or CBD, and be approved by the Ministry of Health before they can be prescribed. The scheme does not legalise raw plant material for general use; the legal product is a manufactured pharmaceutical. The raw flower is available, but only through a prescription and dispensed by a pharmacy. This is the single most important legal boundary to understand.

Key legal and regulatory points (New Zealand, effective 2020 onward): - The Medicinal Cannabis Scheme was established under the Misuse of Drugs (Medicinal Cannabis) Amendment Act 2018 and came into force on 1 April 2020. - The Medicinal Cannabis Agency (MCA), part of Medsafe, issues licences for cultivation, manufacture, and supply under the scheme. - Products must meet GMP (Good Manufacturing Practice) standards and be approved by the Ministry of Health before they can be prescribed. - Prescribing is restricted to medical practitioners, and products are dispensed through a pharmacy, not a dispensary or retail outlet. - The Misuse of Drugs Act 1975 governs the legal framework; cannabis remains a controlled drug, but the scheme provides a legal pathway for prescription products. - The raw flower is available, but only as a prescribed pharmaceutical product dispensed through a pharmacy; it is not a “dispensary” product like in some overseas jurisdictions. - Medsafe and the Medicinal Cannabis Agency (MCA) oversee product approval, licensing, and quality standards. - The NZ Formulary lists cannabis products and provides prescribing guidance for clinicians. - Healthify (previously Health Navigator) provides patient-facing information on medicinal cannabis.

Regulatory framework - The Medicinal Cannabis Scheme under the Misuse of Drugs Act 1975 legalises access via prescription; the scheme was fully operationalised on 1 April 2020 (Ministry of Health, 2020). - Products must meet GMP standards and be approved by the Ministry of Health; unapproved products are illegal. - The Medicinal Cannabis Agency (MCA), part of Medsafe, issues licences for cultivation, manufacture, supply, and prescribing. - A prescription is required; it cannot be dispensed over the counter. Only a medical practitioner can prescribe, not a nurse practitioner (as of the 2020 scheme). - The patient pathway: 1) Consult a doctor; 2) Doctor assesses eligibility and obtains informed consent; 3) Doctor writes a prescription; 4) Pharmacy sources a Medsafe-approved product; 5) Pharmacist dispenses and counsels. - Raw cannabis flower is legal to prescribe, but only as a manufactured pharmaceutical product, not as raw plant material for smoking. It is typically vaporised, not smoked. - The Medicinal Cannabis Scheme (MCS) was established under the Misuse of Drugs (Medicinal Cannabis) Amendment Act 2018, with the first products available from 1 April 2020. - Products must be GMP-certified and approved by the Ministry of Health; the Medicinal Cannabis Agency (MCA) administers this. - Medsafe is the regulatory authority that approves finished products and monitors quality. - The NZ Formulary includes cannabis product monographs, but clinicians are not restricted to them. - The patient pathway: GP or specialist assesses eligibility, prescribes a specific product, pharmacy dispenses it, and the patient pays the full cost (no subsidy). - The scheme does not allow smoking raw plant material; products are manufactured pharmaceuticals, including dried flower for vaporisation, oils, capsules, and oral sprays. - Evidence: The strongest evidence is for chronic pain, chemotherapy-induced nausea and vomiting, and spasticity in multiple sclerosis; the weakest is for anxiety, depression, and sleep disorders. - The Medicinal Cannabis Scheme (MCS) was established under the Misuse of Drugs (Medicinal Cannabis) Amendment Act 2018, with regulations effective 1 April 2020. - The Medicinal Cannabis Agency (MCA) is part of Medsafe and issues licences to import, manufacture, and supply. - Products must meet GMP (Good Manufacturing Practice) standards and be approved by the Ministry of Health. - The NZ Formulary lists available products; prescribers use it to choose. - The patient pathway: GP or specialist consultation → prescription → pharmacy dispensing → follow-up. - The “Green Fairness” and “medical cannabis” debate is not part of this page; the legal framework is the Misuse of Drugs Act and the Medicinal Cannabis Scheme. - The Medicinal Cannabis Scheme was established under the Misuse of Drugs (Medicinal Cannabis) Amendment Act 2018, which came into force in April 2020. - The Medicinal Cannabis Agency (MCA) was established in 2020 under Medsafe. - The scheme’s quality standards align with GMP and were published by the Ministry of Health in 2020. - As of 2025, the NZ Formulary lists cannabis products but the evidence base remains limited; most prescribers rely on international systematic reviews. - The NZ Formulary and Healthify are the official patient and prescriber resources for medicinal cannabis in New Zealand.

SECTIONS AND CORE POINTS: - Section 1: What counts as “research” in New Zealand Core points: Distinguish clinical research (trials, observational studies) from regulatory approval (Medsafe product assessment) and real-world evidence (prescriber and patient-reported outcomes). Explain that most “research” patients see is not a clinical trial but a product registration or a retrospective audit. Use the NZ Formulary as the reference standard for prescribing decisions. - Section 2: Where the evidence sits today Core points: Systematic reviews show modest evidence for chronic pain, some evidence for nausea/vomiting in chemotherapy, and limited evidence for epilepsy; most studies are short-term and industry-funded; New Zealand-specific clinical trials are scarce, but the Ministry of Health funds and reviews research. The strongest evidence is for chronic pain in adults (moderate quality), spasticity in multiple sclerosis (moderate), and nausea from chemotherapy (moderate). The weakest is for anxiety, depression, and sleep disorders, where evidence is mixed or low quality. - Section 3: Who is doing the research Core points: The University of Auckland (Centre for Addiction Research), University of Otago (Christchurch), the Medical Cannabis Research Collaborative (MCRC), a New Zealand group, and the Health Research Council of New Zealand (HRC) fund and conduct studies. Medsafe’s Medicinal Cannabis Agency regulates the scheme. The Ministry of Health publishes the Medicinal Cannabis Scheme guidance. Clinical trials are registered with the Australian New Zealand Clinical Trials Registry (ANZCTR). - Section 4: The regulatory framework - Section 5: The patient pathway - Section 6: Cannabinoids and products - Section 7: Understanding the evidence - Section 8: Safety and daily life - Section 9: Costs and access - Section 10: Checklist for patients and prescribers - Section 11: Where to go from here

The one-paragraph summary

Medicinal cannabis in New Zealand is a regulated pharmaceutical pathway under the Misuse of Drugs Act, not a general licence to use cannabis. The scheme legalises access via a prescription from a medical practitioner, and products must meet GMP standards and be approved by the Ministry of Health. The thing newcomers most often get wrong is that “legal medicinal cannabis” does not mean a patient can legally smoke raw plant material or buy unregulated products; the legal product is a manufactured pharmaceutical, and the raw flower, while available, is prescribed and dispensed through a pharmacy, not a dispensary.

How the Medicinal Cannabis Scheme works

New Zealand’s Medicinal Cannabis Scheme is administered by the Medicinal Cannabis Agency (MCA), which sits within Medsafe, New Zealand’s medicines regulator. The scheme was established under the Misuse of Drugs (Medicinal Cannabis) Amendment Act 2018 and became fully operational in April 2020. Under the scheme, a medical practitioner can prescribe a CBD or THC product that meets GMP standards and has been notified to the Ministry of Health. The legal product is a manufactured pharmaceutical, not raw plant material bought from a dispensary or online vendor. The raw flower is available, but it must be prescribed and dispensed through a pharmacy, and it must meet the same GMP and notification requirements as oils or capsules.